Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RHI
|
|||
| Former ID |
DAP000760
|
|||
| Drug Name |
Trifluridine
|
|||
| Synonyms |
Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Virus infection [ICD-11: 1A24-1D9Z] | Approved | [1], [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Monarch Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H11F3N2O5
|
|||
| Canonical SMILES |
C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
|
|||
| InChI |
1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
|
|||
| InChIKey |
VSQQQLOSPVPRAZ-RRKCRQDMSA-N
|
|||
| CAS Number |
CAS 70-00-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
626314, 7847457, 7980831, 8139891, 8153936, 12014784, 12149237, 14751529, 14849367, 24900027, 29225252, 46506192, 50054714, 56422883, 57323294, 77174799, 87560183, 93815015, 103321204, 104023317, 104253375, 104311541, 118048237, 124757493, 124800643, 125164297, 126667216, 129521334, 131404691, 134223275, 134338045, 134971818, 135681084, 135692274, 136369804, 137000771, 137005241, 137213977, 144205964, 152058901, 160963778, 163835390, 170464911, 172092201, 172919625, 174483143, 175266936, 175612130, 176484794, 179116934
|
|||
| ChEBI ID |
CHEBI:75179
|
|||
| ADReCS Drug ID | BADD_D02283 | |||
| SuperDrug ATC ID |
S01AD02
|
|||
| SuperDrug CAS ID |
cas=000070008
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Mycoplasmatales | ||||
|
Studied Microbe: Mycoplasma
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Microbial Enzyme | Mycoplasma encoded nucleoside phosphorylase | |||
| Metabolic Effect | Decrease activity | |||
| Description | Trifluridine can be metabolized by the mycoplasma encoded nucleoside phosphorylase of Mycoplasma, which results in the decrease of the drug's activity. | |||
|
Studied Microbe: Mycoplasma hyorhinis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Microbial Enzyme | Thymidine phosphorylase | |||
| Metabolic Effect | Decrease activity | |||
| Description | Trifluridine can be metabolized by the thymidine phosphorylase of Mycoplasma hyorhinis, which results in the decrease of the drug's activity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides caccae was decreased by Trifluridine (adjusted p-values: 2.24E-04). | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Trifluridine (adjusted p-values: 1.60E-04). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Trifluridine (adjusted p-values: 1.92E-03). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Trifluridine (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Trifluridine (adjusted p-values: 1.80E-05). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Trifluridine (adjusted p-values: 7.76E-05). | |||
|
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides xylanisolvens was decreased by Trifluridine (adjusted p-values: 5.51E-07). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Trifluridine (adjusted p-values: 1.96E-05). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Trifluridine (adjusted p-values: 6.00E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Erysipelatoclostridium ramosum was decreased by Trifluridine (adjusted p-values: 8.41E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Trifluridine (adjusted p-values: 2.39E-05). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8697). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074311. | |||
| REF 3 | Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.